Targeted Thrombolytic Enzymes Delivery

Abstract

The intravascular delivery of thrombolytic medicines is required due to the small molecular sizes of the medications, resulting in systemic effects and the induction of the lytic state. Although the dose of tPA is higher than that encountered by a healthy organism, it is only partly provided (0.9 mg/kg for stroke, not more than 90 mg and100 mg for myocardial infarction) due to the rapid degradation of tPA upon delivery. Its blood lodging period is just a few minutes, as opposed to the newer type (Tenecteplase, TNKase®), which has a somewhat longer time to lodge blood.